Cargando…

Novel Redirected T–Cell Immunotherapies for Advanced Prostate Cancer

Immunotherapy has failed to achieve durable remissions in advanced prostate cancer patients. More potent T-cell–redirecting strategies may be needed to overcome the immunologically exclusive and suppressive tumor microenvironment. Clinical trials are underway, seeking to define the optimal target fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dorff, Tanya B., Narayan, Vivek, Forman, Stephen J., Zang, Peter D., Fraietta, Joseph A., June, Carl H., Haas, Naomi B., Priceman, Saul J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866199/ https://www.ncbi.nlm.nih.gov/pubmed/34675084 http://dx.doi.org/10.1158/1078-0432.CCR-21-1483

Ejemplares similares

The new era of prostate-specific membrane antigen-directed immunotherapies and beyond in advanced prostate cancer: a review
por: Martin, Felicity C., et al.
Publicado: (2023)

Cardiovascular Toxicity During Advanced Prostate Cancer Treatment: Minding the Heart
por: Dorff, Tanya, et al.
Publicado: (2023)

Advancing together and moving forward: Combination gene and cellular immunotherapies
por: Priceman, Saul J., et al.
Publicado: (2022)

L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice
por: Hong, Hao, et al.
Publicado: (2016)

Development of chimeric antigen receptor (CAR) T-cell immunotherapy for glioblastoma targeting epidermal growth factor receptor variant III (EGFRvIII)
por: Park, Anthony K, et al.
Publicado: (2015)

Development and optimization of PSCA-specific CAR T cells for the treatment of bone metastatic prostate cancer
por: Gerdts, Ethan, et al.
Publicado: (2015)

PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages
por: Yamaguchi, Yukiko, et al.
Publicado: (2022)

Redirecting the focus of cancer immunotherapy to premalignant conditions
por: Young, M. Rita I.
Publicado: (2017)

Bone-targeted therapies to reduce skeletal morbidity in prostate cancer
por: Dorff, Tanya B, et al.
Publicado: (2018)

Development of chimeric antigen receptor-redirected T cell therapy targeting L1-CAM in ovarian cancer
por: Hong, Hao, et al.
Publicado: (2013)

Hormonal manipulation in androgen signaling: a narrative review on using novel androgen therapy agents to optimize clinical outcomes and minimize side effects for prostate cancer patients
por: Lyou, Yung, et al.
Publicado: (2021)

Wnt/β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2021)

Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
por: Mensali, Nadia, et al.
Publicado: (2019)

Redirecting host preexisting influenza A virus immunity for cancer immunotherapy
por: Chaganty, Bharat K. R., et al.
Publicado: (2021)

Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell–Redirected Bispecific Antibodies
por: Lussana, Federico, et al.
Publicado: (2021)

Enhancing T cell persistence of CAR-redirected T cells in solid tumors
por: Guedan, Sonia, et al.
Publicado: (2014)

Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
por: Mensali, Nadia, et al.
Publicado: (2019)

Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies
por: Abbott, Rebecca C., et al.
Publicado: (2020)

Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection
por: Yu, Steven S, et al.
Publicado: (2016)

Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity
por: Murad, John P., et al.
Publicado: (2021)

A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells
por: Lund, Maria E., et al.
Publicado: (2020)

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy
por: Bhatia, Vipul, et al.
Publicado: (2023)

Redirecting abiraterone metabolism to fine tune prostate cancer anti-androgen therapy
por: Li, Zhenfei, et al.
Publicado: (2016)

Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
por: Fromm, George, et al.
Publicado: (2018)

Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
por: Lin, Tsung-Yi, et al.
Publicado: (2021)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

Bispecific Antibody Format and the Organization of Immunological Synapses in T Cell-Redirecting Strategies for Cancer Immunotherapy
por: Carrasco-Padilla, Carlos, et al.
Publicado: (2022)

Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma
por: Li, Kesang, et al.
Publicado: (2015)

A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus
por: Koh, Sarene, et al.
Publicado: (2013)

T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent Advances
por: Messéant, Ondine, et al.
Publicado: (2021)

DCs redirect T cell traffic
por: Van Epps, Heather L.
Publicado: (2005)

Redirecting splicing with bifunctional oligonucleotides
por: Brosseau, Jean-Philippe, et al.
Publicado: (2014)

Monitoring and redirecting virus evolution
por: Moratorio, Gonzalo, et al.
Publicado: (2018)

Preoperative planning for redirective, periacetabular osteotomies
por: Albers, Christoph E, et al.
Publicado: (2017)

Redirecting adenovirus to pulmonary endothelium by cationic liposomes
por: Ma, Z, et al.
Publicado: (2002)

Immune Response to Sipuleucel-T in Prostate Cancer
por: Thara, Eddie, et al.
Publicado: (2012)

Identification of Targets to Redirect CAR T Cells in Glioblastoma and Colorectal Cancer: An Arduous Venture
por: Ponterio, Eleonora, et al.
Publicado: (2020)

Development of HER2-specific chimeric antigen receptor T cells for the treatment of breast-to-brain metastasis
por: Priceman, Saul, et al.
Publicado: (2015)

Sipuleucel-T: immunotherapy for advanced prostate cancer
por: Olson, Brian M, et al.
Publicado: (2011)

Progression in immunotherapy for advanced prostate cancer
por: Liang, Hao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_opfotuch3lnrnpjg4291g8mmr7